secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001213900-25-036109
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed invests $36.9M in Alpha Tau, acquires 14.1M shares at $2.612/share
-------------------------------------------------------------------------

- Oramed subsidiary purchased ~14.1M shares of Alpha Tau (NASDAQ: DRTS) for $36.9M ($2.612/share) via registered direct offering.
- Oramed gets right to nominate two directors to Alpha Tau board; board size capped at 8 without Oramed's consent.
- Concurrent 3-year IR/PR services agreement; Oramed receives $3M fee plus warrants to buy ~3.24M shares at $3.474-$3.90.
- Partnership aims to support Alpha Tau's alpha-radiation cancer therapy Alpha DaRT, including US trials and manufacturing scale-up.
- Oramed CEO Nadav Kidron cites alignment in transforming therapeutic delivery; governance role allows strategic influence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025036109/0001213900-25-036109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025036109/ea0239800-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-036109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer